• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Court Ruling Requires Sponsors to Submit 10 Years of Retroactive Clinical Trial Data

Court Ruling Requires Sponsors to Submit 10 Years of Retroactive Clinical Trial Data

Gavel-360x240.png
February 29, 2020
Tamra Sami

Calling an HHS interpretation of a final rule on a 2007 law “unlawful,” a federal judge ruled last week that the results from up to 12,000 trials not reported to ClinicalTrials.gov will have to be added to the trial database.

The ruling centered on a clause in a 2017 final HHS regulation that the judge said effectively created an exemption for drug- and devicemakers to post their trials, saying that “pre-rule, pre-approved (applicable clinical trials)” were not subject to the ct.gov posting requirement. “HHS’s contrary interpretation, which the agency announced in the preamble of the Final Rule, is unlawful and must be set aside,” the judge wrote.

HHS misinterpreted the 2007 Food and Drug Administration Amendments Act (FDAAA), which required clinical trial sponsors to submit clinical trial results to ct.gov and to register the trial 21 days after the first patient enrolls, Judge Naomi Reice Buchwald wrote in her ruling.

“The Court accordingly finds that the FDAAA unambiguously requires responsible parties to submit, and defendants to include on ClinicalTrials.gov, Basic Results for pre-rule, pre-approval (applicable clinical trials,” the ruling said.

Basic results are defined as demographic and baseline characteristics of a trial’s patient sample, primary and secondary outcomes, a point of contact for scientific information about the trial’s results, and whether there is an agreement between the sponsor and the principal investigator (PI) that restricts the PI’s ability to discuss or publish the trial’s results after its completion.

Buchwald did not state in the ruling how quickly the results will need to be posted to ct.gov. FDAAA allows the government to fine sponsors who fail to submit their results $10,000 a day, although no fines have been levied to date.

HHS could appeal the court’s ruling. But for now, HHS is saying that it is “evaluating the Court’s decision with the Department of Justice to determine our next steps.”

The suit, Charles Seife and Peter Lurie v. HHS, et al., was filed in the U.S. District Court for the Southern District of New York.

Read the ruling here: https://bit.ly/2T3qdAz.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing